Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients

Documenti analoghi

• Circulating levels of galectin‐9 are a potential biomarker of survival in advanced non‐small‐cell lung cancer
  di: Guilherme Vieira de Mendonça Filho, et al.
  Pubblicazione: (2024)
• Expression of CD44highCD24Low cells, SOX2, and STAT3 transcription factors on peripheral blood and tumor tissue of penile squamous cell carcinoma
  di: Felipe Dubourcq de Barros, et al.
  Pubblicazione: (2024)
• Prognostic role of SOX2 and STAT3 expression on circulating T lymphocytes and CD44+/CD24neg cells in the locally advanced and metastatic breast cancer
  di: Denise V. Sobral, et al.
  Pubblicazione: (2024)
• Can cell‐free DNA (cfDNA) in pleural lavage serve as a predictive and prognostic biomarker among surgically treated Stage I−III a nonsmall cell lung cancer (NSCLC)? A pilot study
  di: Jyoutishman Saikia, et al.
  Pubblicazione: (2024)
• Survival and pulmonary function in stage IA non‐small cell lung cancer after sublobar resection versus lobectomy: An updated meta‐analysis
  di: Isadora Mamede, et al.
  Pubblicazione: (2024)